With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment ...

President Trump’s chief cost-cutter cheered an effort to persuade federal workers to quit — in a fashion that closely ...

Health care, ride sharing, and the emerging world of YouTube entertainers are among industries leading investors have picked ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Asit Sharma: Well, I am chilling with the fam, but in an alternate universe, Ricky, I'm showing up with a few beers and a pack of cards at your house to spend ... drug space after a monster 2022, 2023 ...

If Eli Lilly has its way, this may be the future ... in an interview with Business Insider. Like Ozempic, the new pill is designed to mimic the glucagon-like peptide 1 hormone that our bodies ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.